Our combined results suggest that two pathways are activated in drug resistance of NRAS mutant melanoma and that CD133 contributes to at least one of these pathways via AKT and the BCL-2 family, while the other pathway involves MAPK. The gene discussed is PROM1; the disease is melanoma.